Quick Facts

• Treats: Active duodenal ulcers, short-term management (up to 8 weeks).
• Prevents: Recurrence of duodenal ulcers (maintenance therapy).

---

Mulcatel is a prescription medication utilized for the management and care of certain gastrointestinal conditions. Its primary approved therapeutic indication is for the short-term treatment of active duodenal ulcers, typically for a period up to eight weeks. It is also utilized for maintenance therapy to prevent the return of duodenal ulcers once they have healed.

Therapeutic Action and Support

The medication's benefit comes from a local, protective action rather than being absorbed systemically. When Mulcatel comes into contact with the acidic environment of the stomach, it transforms into a viscous substance that forms a coating at the site of the ulcer. This coating acts as a physical shield, protecting the damaged tissue from the digestive actions of stomach acid, pepsin, and bile salts. This barrier helps the natural healing process of the ulcerated area.

Additional uses that may be prescribed by a healthcare provider include treatment for conditions such as gastritis, gastroesophageal reflux disease (GERD), and certain forms of mucositis. However, its core indication remains the treatment of duodenal ulcers and their prevention in a maintenance setting.

Eligibility Map: Who can and cannot use Mulcatel — Official Regulatory Information

Eligibility Scope

Populations	Official Regulatory Status
Adults	Allowed for labeled indications under standard conditions.
Children (Pediatric)	Use Not Established. Safety and effectiveness have not been formally established.
Hypersensitivity	Contraindicated in patients with known allergy to sucralfate or excipients.

Condition-Specific Eligibility Rules

• Renal Impairment: Use with Caution in patients with Chronic Renal Failure. Small amounts of aluminum are absorbed, and impaired renal function (including in patients on dialysis) can lead to aluminum accumulation.
• Gastrointestinal Risk: Caution is required for patients with underlying conditions that may predispose to bezoar formation (e.g., delayed gastric emptying or difficulty swallowing).
• Older Adults: Use requires Caution, reflecting the greater frequency of decreased renal function in this population.

Life-Stage Eligibility Status

• Pregnancy: Classified as Category B by the FDA. Use is conditional and permitted only if clearly needed.
• Lactation: Caution should be exercised when administered to a nursing woman, as it is unknown whether the drug is excreted in human milk.

Connection to the Overall Eligibility Profile

Official regulatory documents define eligibility by establishing an absolute contraindication based on known hypersensitivity and defining specific population-based restrictions tied primarily to age (pediatric use not established) and the patient's capacity for aluminum excretion (renal function and geriatric status). These official constraints limit the drug to populations where the regulatory profile for safe use is established or clearly conditional.

Mulcatel Interactions with other medicines and products

Mulcatel (Sucralfate) is primarily associated with a nonsystemic pharmacokinetic interaction that affects the absorption of certain co-administered oral medications. This interaction is defined by its action of binding to other substances in the gastrointestinal tract, which results in the reduced systemic exposure (bioavailability) of those drugs.

Documented Pharmacokinetic Interaction

To prevent this reduction in bioavailability, the official regulatory profile mandates a timing separation rule. Concomitant oral medicines, including Cimetidine, Digoxin, Fluoroquinolone antibiotics (e.g., Ciprofloxacin), L-thyroxine, Phenytoin, and Ranitidine, must be administered at least 2 hours before a Mulcatel dose. Failure to separate administration may lead to significantly lower concentrations of the co-administered drug.

Pharmacodynamic and Substance Interactions

Co-administration with aluminum-containing products, such as certain antacids, can increase the total body burden of aluminum. For this reason, the official label states that antacids must not be taken within 30 minutes before or after Mulcatel. Furthermore, patients with chronic renal failure are formally noted as having an increased risk of aluminum accumulation and toxicity due to impaired excretion, a specific population-based interaction caution.

Mulcatel (Sucralfate) functions through a highly localized, non-systemic pharmacodynamic process involving physical barrier formation and modulation of intrinsic mucosal defense pathways.

Physical Barrier Formation and Aggressor Neutralization

This mechanism is initiated by an acid-catalyzed chemical action: exposure to low pH triggers the molecule's polymerization into a dense, polyanionic complex that adheres via electrostatic binding to exposed proteins in damaged tissue. This creates an adherent physical barrier that restricts hydrogen ion ( H^+) back-diffusion and facilitates the adsorption and inhibition of proteolytic enzymes, such as pepsin, and mucosal irritants, such as bile salts.

---

Cytoprotective Trophic Modulation

This domain addresses the drug's role in stimulating local biological defense mechanisms. The localized presence of the drug stimulates the synthesis and release of endogenous prostaglandins (E2), which increases the secretion of mucus and bicarbonate ( HCO3^-). Furthermore, the complex binds and shields local growth factors (e.g., EGF) from enzymatic degradation, which facilitates epithelial cell regeneration and restitution at the cellular level.

How to Use Mulcatel: Official Administration Guidelines

The usage of Mulcatel (Sucralfate) is defined by a specific set of administration rules based on its local, non-systemic action as a mucosal protectant. Official instructions detail the approved route, frequency, and relationship to food and other oral treatments to ensure proper function in the upper gastrointestinal tract.

---

Administration Scope

Instruction	Official Guideline
Route of Administration	Must be administered via the oral route only; intravenous use is prohibited.
Dosing Schedule	Active Duodenal Ulcer: 1 gram four times a day (QID). Maintenance Therapy: 1 gram twice a day (BID).
Forms and Strengths	Available as a 1 gram tablet and a 1 gram per 10 mL oral suspension.

---

Procedural Administration Conditions

Mulcatel must be taken on an empty stomach. The standard QID regimen involves taking the medication one hour before each meal and at bedtime. For the medication to work correctly, it is critical to observe specific timing constraints with other substances.

• Antacid Separation: Antacids should not be taken within 30 minutes before or after a dose of Mulcatel.
• Other Oral Medications: Other oral drugs generally require a separation of at least two hours from Mulcatel to prevent potential interference with absorption.

Course Duration and Population Use

Treatment for an active duodenal ulcer is typically considered short-term, continuing for a period of 4 to 8 weeks. Once the acute phase concludes, patients may transition to the BID dose for maintenance therapy to help prevent recurrence. For older adults, official guidance suggests a cautious dose selection, often starting at the lower end of the dosing range due to the greater prevalence of decreased organ function in this population.

Research evidence / Overview of Studies for Mulcatel

---

Evidence for Use in Active Duodenal Ulcers

Mulcatel was studied for its use in short-term management of active duodenal ulcers, a condition characterized by functional limitations and periods of heightened symptoms. The research base primarily consists of short-term, randomized controlled trials (RCTs), many of which were double-blind and multicenter. These studies focused on adult patients whose ulcers were confirmed by visual examination.

The research examined outcomes related to physiological strain or stress measured by follow-up procedures (e.g., ulcer healing rates), along with patient-reported outcomes describing perceived discomfort related to the ulcers. Findings describe patterns observed in the studies related to the frequency of complete ulcer re-epithelialization.

---

Evidence for Use in Preventing Ulcer Recurrence (Maintenance Studies)

Mulcatel was also studied for its use as maintenance therapy to prevent the return of duodenal ulcers once the acute episode has undergone change. The evidence includes randomized controlled trials (RCTs) that involved adult patients who were tracked following the complete resolution of their duodenal ulcer.

The research examined outcomes describing episodic or acute changes, such as the rate of ulcer recurrence or relapse, over intermediate-term observation periods. Findings indicate patterns related to the occurrence of ulcer relapse when patients were monitored over defined time intervals.

---

Research for Other Mucosal Conditions

Research has explored Mulcatel for other gastrointestinal conditions, including gastric ulcers, gastritis, gastroesophageal reflux disease (GERD), and mucosal injuries. This evidence base is more diverse and includes comparative clinical trials and systematic reviews.

Regarding GERD, studies monitored outcomes related to physical discomfort. Research reports regarding changes in symptom scores and outcomes linked to inflammatory or irritative states (e.g., endoscopic healing) for this condition findings were mixed. For conditions like radiation-induced mucositis, evidence quality varies across studies; the reported changes in symptom severity were not always found to be statistically significant across all trials.

---

What the Research Still Does Not Characterize

Long-term outcomes are not fully established, particularly concerning usage beyond a few months. Evidence quality varies across studies, especially for uses outside the core duodenal ulcer indication. Furthermore, data for certain groups remain insufficient, meaning the results apply only to the populations studied. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Sucralfate for the healing of duodenal ulcers: a review

Common questions about Mulcatel (FAQ)

Q: Can elderly patients generally use Mulcatel?

A: Official labeling indicates that Mulcatel can be used by older adults. However, regulatory documents suggest a cautious dose selection, often starting at the lower end of the range. This caution reflects the greater likelihood of decreased kidney function in this population, which is noted in the official labeling.

Q: Is Mulcatel ever prescribed to children or teens?

A: According to official regulatory documents, the safety and effectiveness of Mulcatel have not been established in pediatric patients. Its use has not been formally established in pediatric patients.

Q: Does the time of day matter when taking Mulcatel?

A: Yes, the timing is important because the medication is designed to work best on an empty stomach. The standard recommended schedule involves taking it about one hour before meals and at bedtime. The recommended schedule is in place to ensure proper localized action in the upper digestive tract.

Q: Are there any restrictions on driving or operating machinery while on Mulcatel?

A: While regulatory documents do not list a specific driving restriction, official information reports adverse effects such as dizziness, sleepiness (somnolence), and vertigo. Patients should be aware of these potential effects when performing tasks that require mental alertness, such as driving or operating machinery.

Q: What should I know about the long-term effects of taking Mulcatel?

A: The official indication is for the short-term treatment of active ulcers. For patients with impaired kidney function, regulatory documents indicate that monitoring of renal function may be necessary due to the risk of aluminum accumulation.

Q: How quickly does Mulcatel usually start working?

A: Regulatory documents describe Mulcatel's action as localized and non-systemic, meaning it forms a physical barrier that acts immediately upon contact with the ulcer site, without needing to be absorbed into the bloodstream.

Q: What is the time frame for seeing any expected effects from Mulcatel?

A: Official treatment for an active duodenal ulcer is typically continued for 4 to 8 weeks unless healing is confirmed by a medical professional. The 4- to 8-week period is the established timeframe for the treatment course, which is based on the healing rates observed in clinical studies.

Q: Is Mulcatel a long-term treatment or just for short periods?

A: Mulcatel is officially indicated for short-term treatment of active duodenal ulcers, typically up to eight weeks. A lower dose is sometimes used for maintenance therapy, which is intended to help prevent the ulcer from returning.

Q: Is it normal to feel a mild headache when first starting Mulcatel?

A: Headache is listed as an adverse effect reported in less than 0.5% of patients during clinical trials. Regulatory documents report the frequency of adverse effects, but do not comment on whether a specific symptom is considered 'normal' for an individual starting the medication.

Q: What are the most commonly reported side effects of Mulcatel?

A: The most frequently reported adverse reaction in clinical trials is constipation, which occurred in approximately 2% of patients. Other gastrointestinal, nervous system, and skin effects are reported less frequently.

Q: Does Mulcatel affect sleep patterns?

A: Official documents list nervous system adverse effects such as insomnia (difficulty sleeping) and sleepiness (somnolence). These effects were reported in a small percentage (less than 0.5%) of patients in clinical studies.

Q: Can Mulcatel cause stomach upset or digestive changes?

A: Yes, regulatory documents report several gastrointestinal adverse effects. These include diarrhea, dry mouth, flatulence, gastric discomfort, indigestion, nausea, and vomiting.

Q: Are there any signs that a side effect from Mulcatel is becoming serious?

A: Official documents list rare but serious complications, such as bezoar formation (a mass in the digestive tract) and symptoms of a hypersensitivity reaction (e.g., severe swelling or trouble breathing). These events represent rare, serious complications noted in official warnings.

Q: What if I forget to take a dose of Mulcatel?

A: General patient guidance suggests taking the missed dose as soon as it is remembered, unless it is almost time for the next scheduled dose. Regulatory guidance includes a caution against taking a double dose to make up for a missed dose.

Q: Can Mulcatel affect fertility in men or women?

A: Reproduction studies conducted in rats did not indicate any potential for fertility impairment at doses many times higher than the typical human dose.

Q: What kind of studies support the use of Mulcatel?

A: The core evidence that supports the approved use of Mulcatel is primarily derived from short-term, randomized controlled trials (RCTs). These studies focused specifically on adult patients with duodenal ulcers to evaluate healing and maintenance.

Q: What does 'contraindication' mean in relation to Mulcatel?

A: A contraindication is an official regulatory statement that the medication must not be used. For Mulcatel, this applies if a patient has a known hypersensitivity reaction (allergy) to the active substance (Sucralfate) or to any of its inactive ingredients.

Q: How does Mulcatel's intended use differ from its chemical makeup?

A: The chemical makeup as an aluminum salt allows the drug to be minimally absorbed by the body. Its intended use is based on this property, allowing it to act locally by forming a physical protective coating over the ulcer site.

Q: Is it possible to develop a tolerance to Mulcatel over time?

A: Clinical reviews suggest that Mulcatel is generally well tolerated when administered over the typical treatment periods defined in studies. This finding indicates a low potential for the development of acute tolerance.

Q: Can Mulcatel be split or crushed if I have trouble swallowing pills?

A: Official labeling states caution is necessary for patients with conditions that may impair swallowing. While tablet manipulation is not specified, an oral suspension form is officially available for patients who have difficulty swallowing the tablets.

Q: Are generic versions of Mulcatel available?

A: Yes, generic versions of the active ingredient (Sucralfate) in both the tablet and oral suspension dosage forms are approved by regulatory agencies and are available to patients.

Q: Does taking Mulcatel require regular monitoring or blood tests?

A: Official documents state that it may be useful to monitor renal (kidney) function in elderly patients and patients with existing impaired renal function. This is a specific precaution due to the risk of aluminum accumulation in this population.

Q: Can Mulcatel be taken by people with diabetes?

A: Post-marketing cases of hyperglycemia (high blood sugar) have been reported by regulatory bodies. This potential effect may be a consideration for patients who have diabetes.

Q: Is there a link between Mulcatel and changes in mood?

A: The official label reports nervous system effects like insomnia (difficulty sleeping) and sleepiness (somnolence). However, no specific link to broader changes in mood or depression is listed in the adverse reaction sections.

Q: Does Mulcatel have a risk of dependence or withdrawal?

A: Since the drug is only minimally absorbed by the body, the risk of acute overdosage is minimal. Official documents provide no statement or evidence regarding the potential for dependence or withdrawal.

Q: Is there a maximum length of time Mulcatel is studied for use?

A: Clinical studies primarily support the use of Mulcatel for short-term treatment of active duodenal ulcers for up to 8 weeks. Maintenance studies examine use for longer periods to prevent recurrence.

How to Store and Dispose of Mulcatel (Sucralfate)

Mulcatel (Sucralfate) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The medication must be kept in its original container, which should remain tightly closed in a dry place and protected from light. A critical restriction for the Oral Suspension is the requirement to AVOID FREEZING.

Consistent with regulatory requirements for all medications, Mulcatel must be stored out of the sight and reach of children.

Unused or expired product should be disposed of by utilizing a drug take-back program. If a program is unavailable, the product must be mixed with an undesirable substance, sealed in a bag, and placed in the household trash. The product must not be flushed down the drain or released into water systems.